Tech2 Nov 2026
Anthropic Expands Claude Into Drug Discovery to Tackle Clinical and Operational Bottlenecks
Anthropic has escalated its ambitions in biopharma by deploying its Claude AI models directly into active drug programs and acquiring early-stage biotech assets. Partnering with major pharmaceutical organizations and operating its own molecular biology laboratory, the company aims to move beyond molecular design into overcoming administrative, chemical, and operational bottlenecks. While early preclinical results show substantial gains in trial preparation and antibody optimization, researchers caution that human safety trials remain a formidable constraint.
By NeuraFeed